ITWO - ETF AI Analysis
Top Page
ProShares Russell 2000 High Income ETF (ITWO)
Rating:58Neutral
Price Target:―
Positive Factors
Strong Year-To-Date Performance
The ETF has delivered strong gains so far this year, indicating solid recent results for investors.
Strong-Performing Top Holdings
Many of the largest positions have shown strong performance this year, helping support the fund’s overall returns.
Broad Sector Diversification
The fund is spread across many sectors, including health care, financials, technology, and industrials, which helps reduce the impact of weakness in any single industry.
Negative Factors
Moderately High Expense Ratio
The fund’s fees are not especially low, which means a larger slice of returns goes toward costs instead of staying with investors.
Heavy U.S. Market Exposure
With most assets in U.S. companies and very limited foreign exposure, the ETF is highly sensitive to movements in the U.S. market.
Recent Short-Term Weakness
The ETF has shown slightly negative performance over the past month, suggesting some short-term volatility that investors should be prepared for.
ITWO vs. SPDR S&P 500 ETF (SPY)
AUM184.81M
RegionNorth America
Expense Ratio0.55%
Beta0.96
IssuerProShares
Inception DateSep 04, 2024
Dividend Yield7.46%
Asset ClassEquity
Index TrackedCboe Russell 2000 Daily Covered Call Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume25,076
30 Day Avg. Volume27,080
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
57.04Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1949
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ITWO Summary
ProShares Russell 2000 High Income ETF (ITWO) is an exchange-traded fund that follows the Russell 2000 High Dividend Index, focusing on smaller U.S. companies that pay relatively high dividends. It owns a wide mix of businesses across health care, financials, technology, and more, including names like Moog and ViaSat. Someone might invest in ITWO to get both diversification into small-cap stocks and potential income from dividends. A key risk is that small-cap stocks can be more volatile than larger companies, so the value of this ETF can go up and down sharply with the market.
How much will it cost me?The ProShares Russell 2000 High Income ETF (ITWO) has an expense ratio of 0.55%, which means you’ll pay $5.50 per year for every $1,000 invested. This is slightly higher than average because it is actively managed to focus on small-cap companies with high dividend yields, requiring more research and strategy compared to passively managed funds. Overall, it balances growth and income potential for investors.
What would affect this ETF?The ProShares Russell 2000 High Income ETF (ITWO) could benefit from a strong U.S. economy, as small-cap companies often thrive during periods of economic growth and innovation, particularly in sectors like technology and healthcare, which are heavily represented in this fund. However, rising interest rates or economic slowdowns could negatively impact small-cap stocks and dividend-paying companies, as borrowing costs increase and consumer spending declines. Regulatory changes or sector-specific challenges in industries like energy or financials may also influence the ETF's performance.
ITWO Top 10 Holdings
ITWO is leaning into U.S. small caps with a noticeable tilt toward health care and tech, and a mix of rising stars and laggards shaping returns. High-momentum names like 10x Genomics and Twist Bioscience have been powering ahead, giving the fund a growth-flavored boost despite their profitability hurdles. On the other side, JFrog and BrightSpring Health Services have seen more mixed, recently lagging action, acting as a bit of a brake. Financials like UMB Financial add a steadier, income-oriented backbone, helping balance this volatile, all‑U.S. small-cap lineup.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Twist Bioscience | 0.39% | $725.31K | $12.42B | 507.24% | 43 Neutral | |
| Moog | 0.35% | $651.23K | $12.44B | 88.57% | 73 Outperform | |
| JFrog | 0.34% | $620.77K | $11.78B | 98.67% | 73 Outperform | |
| 10x Genomics | 0.33% | $605.88K | $12.18B | 633.33% | 60 Neutral | |
| BrightSpring Health Services, Inc. | 0.30% | $560.69K | $11.92B | 112.45% | 67 Neutral | |
| UMB Financial | 0.30% | $558.62K | $9.94B | 9.57% | 77 Outperform | |
| Glaukos | 0.30% | $548.41K | $9.66B | 87.34% | 61 Neutral | |
| ViaSat | 0.29% | $528.05K | $9.92B | 124.58% | 56 Neutral | |
| Hut 8 | 0.28% | $519.89K | $11.05B | 128.67% | ― | |
| InterDigital | 0.28% | $517.71K | $8.65B | -1.17% | 76 Outperform |
ITWO Technical Analysis
Neutral
―
Price Trends
44.88
Negative
44.64
Negative
42.08
Positive
Market Momentum
-0.56
Positive
40.85
Neutral
17.02
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ITWO, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 43.82, equal to the 50-day MA of 44.88, and equal to the 200-day MA of 42.08, indicating a neutral trend. The MACD of -0.56 indicates Positive momentum. The RSI at 40.85 is Neutral, neither overbought nor oversold. The STOCH value of 17.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ITWO.
ITWO Peer Comparison
Comparison Results
Performance Comparison
ITWO
ProShares Russell 2000 High Income ETF
43.35
6.35
17.16%
SFLO
VictoryShares Small Cap Free Cash Flow ETF
―
―
―
OUSM
OShares U.S. Small-Cap Quality Dividend ETF
―
―
―
BBSC
JPMorgan BetaBuilders U.S. Small Cap Equity ETF
―
―
―
JHSC
John Hancock Multifactor Small Cap ETF
―
―
―
EES
WisdomTree U.S. SmallCap Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents